Bioregnum channel feed – Endpoints News

Bioregnum channel feed

Exclusive: Helsinn chief Riccardo Braglia spells out a blockbuster plan to take the family pharma public — with an eye on new cancer drug deals, spinout

4 years ago

The $70B question: What’s Pfizer going to do with all that Covid vaccine cash?

5 years ago

There’s a new team occupying the executive suite at Merck. And they’ve got a new game plan

5 years ago

FDA to CytoDyn: Those 2 Covid trials you keep touting both failed on all endpoints and your subgroup analysis doesn't help. Are we clear now?

5 years ago

Insider account of Roivant's SPAC deal — and that $7.3B valuation — reveals a few secrets as Matt Gline positions the company as the new ‘Big Pharma’

5 years ago

'Dude, you're getting a Dell' — as a new deep-pocket biotech investor

5 years ago

Let’s make that $1B-plus: Abingworth gathers more cash, this time for its late-stage poker game. And we learned that even a biotech nuclear winter has its advantages

5 years ago

OcuWho? Star dealmaker turned aesthetics czar Brent Saunders flips back into biotech. But who’s he teaming up with now?

5 years ago

Josh Bilenker and Jeff Engelman bundle a mother lode of cash for their stealthy startup, attracting a who's who of biotech investors

5 years ago

Now reimagining home, office schedules: Novartis CEO Vas Narasimhan sees a new normal in the post-Covid era

5 years ago

Damn the critics, Biogen CEO Vounatsos orders full speed ahead on prepping a controversial aducanumab launch as FDA decision looms

5 years ago

A top analyst sees Pfizer and Moderna seizing a $38B prize as safety frets sideline global vaccine players

5 years ago

Recursion founders gin fortunes as IPO backers shower $436M on one of the biggest boasts in AI — based on some very small deals

5 years ago

Activist investor grabs a multibillion-pound stake in GlaxoSmithKline, triggering buzz about a looming showdown at the listless giant

5 years ago

Can he pick them? A high-profile Wall Street analyst jumps into biotech as CFO of an oncology upstart

5 years ago

Roger Perlmutter’s latest ‘retirement’ gig opens a door to the bustling China biotech scene

5 years ago

A departing CMO pens a sad farewell as he heads back to the UK biopharma scene

5 years ago

Eli Lilly touts a 'constellation' of successes with their PhII Alzheimer’s study — but disappointing failures drag down shares

5 years ago

Jeff Hatfield assembles a syndicate with some A-list public investors in the mix as Vividion adds $135M raise

5 years ago

The $1M IPO bonus, decent pay and a nice equity stake to mark the upside: How does Mark McKenna's comp package stack up in the Nasdaq rush?

5 years ago

Biopharma execs routinely shun revealing the hard truth when it comes to RTFs. And some people at the FDA think that's a big problem

5 years ago

One of the giant vaccine players pushes back against a ‘fundamental shift’ spurred by mRNA. But is the CEO just whistling past the graveyard?

5 years ago

Is it time to stock up on wine? This pandemic could stretch out — and that has some major market implications

5 years ago

AstraZeneca CEO Pascal Soriot severs an unusual board connection, steering clear of conflicts while retaining important alliances

5 years ago

First page Previous page 4 5 678 9 10 Next page Last page